Evidence map›Paper›PMID 38086815›Full record

ReviewSignal transduction and targeted therapy2023

Therapeutic cancer vaccines: advancements, challenges, and prospects.

Ting Fan, Mingna Zhang, Jingxian Yang, Zhounan Zhu, Wanlu Cao, Chunyan Dong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 320 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
320citing papers in PubMed, 2 pooled it
76.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

320 citing papers in PubMed, 2 syntheses or guidelines pooled it, 466 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  19. Review
  20. Article

260 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ting FanDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-4557-8888
Mingna ZhangPostgraduate Training Base, Shanghai East Hospital, Jinzhou Medical University, Shanghai, 200120, China.
Jingxian YangDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Zhounan ZhuDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Wanlu CaoDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China. Wanlu724576084@hotmail.com.
Chunyan DongDepartment of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China. cy_dong@tongji.edu.cn.
Tongji University · CNShanghai East Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81573008National Natural Science Foundation of China (National Science Foundation of China) 81860547National Natural Science Foundation of China (National Science Foundation of China) 82203861
6 · The paper itself

Abstract

With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades. Recently, therapeutic cancer vaccines have shown promise by eliciting de novo T cell responses targeting tumor antigens, including tumor-associated antigens and tumor-specific antigens. The objective was to amplify and diversify the intrinsic repertoire of tumor-specific T cells. However, the complete realization of these capabilities remains an ongoing pursuit. Therefore, we provide an overview of the current landscape of cancer vaccines in this review. The range of antigen selection, antigen delivery systems development the strategic nuances underlying effective antigen presentation have pioneered cancer vaccine design. Furthermore, this review addresses the current status of clinical trials and discusses their strategies, focusing on tumor-specific immunogenicity and anti-tumor efficacy assessment. However, current clinical attempts toward developing cancer vaccines have not yielded breakthrough clinical outcomes due to significant challenges, including tumor immune microenvironment suppression, optimal candidate identification, immune response evaluation, and vaccine manufacturing acceleration. Therefore, the field is poised to overcome hurdles and improve patient outcomes in the future by acknowledging these clinical complexities and persistently striving to surmount inherent constraints.

Indexed as

Cancer VaccinesNeoplasmsAntigens, NeoplasmHumansImmunityImmunotherapyTumor MicroenvironmentAntigens, NeoplasmCancer Vaccines

Identifiers

PMID38086815
PMCPMC10716479
OpenAlexW4389639889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.